Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Clinical Trial

Official title: A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Status Terminated

Clinical Trial Summary

A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Polycythemia
• Polycythemia Vera
• Primary Myelofibrosis
• Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
• Thrombocythemia, Essential
• Thrombocytosis

• NCT number: NCT02226172
• Study type: Interventional
• Source: Pfizer
• Status: Terminated
• Phase: Phase 2
• Start date: October 6, 2014
• Completion date: January 31, 2018